Nektar Therapeutics Insider Jonathan Zalevsky Sells 180 Shares

Jonathan Zalevsky, an insider at Nektar Therapeutics (NASDAQ:NKTR), sold 180 shares of the company’s stock on February 18, 2024. The shares were sold at an average price of $73.00, resulting in a total transaction value of $13,140.00. Following this sale, Zalevsky holds 21,174 shares, valued at approximately $1,545,702, marking a 0.84% decrease in his ownership stake.

The transaction was formally disclosed in a filing with the Securities and Exchange Commission, providing transparency regarding insider trading activities.

Current Market Performance

As of mid-day trading on February 19, 2024, shares of Nektar Therapeutics traded down by 0.2%, reaching $73.73. The trading volume for the day was 997,867 shares, notably below the average volume of 1,533,099 shares. Over the past year, Nektar’s stock has fluctuated significantly, with a fifty-two week low of $6.45 and a high of $74.89. The company currently has a market capitalization of $1.50 billion, a price-to-earnings ratio of -9.25, and a beta of 1.34, indicating a higher volatility compared to the broader market.

Institutional Investor Activity

Recent activity among institutional investors reflects growing interest in Nektar Therapeutics. Notably, BNP Paribas Financial Markets increased its stake by 93.8% during the third quarter, now owning 434 shares valued at $25,000. Additionally, FNY Investment Advisers LLC acquired a new position worth $39,000 in the second quarter.

Other significant movements include Compass Wealth Management LLC’s new stake valued at approximately $88,000 and Bessemer Group Inc.’s substantial increase in shares by 1,741.2%, now totaling 1,565 shares valued at $90,000. The collective investment from institutional investors and hedge funds accounts for 75.88% of Nektar’s stock.

Nektar Therapeutics remains focused on developing innovative drug candidates through its distinct chemistry and immunology platforms. The company is particularly recognized for its polymer conjugate technology, which enables the creation of longer-lasting versions of existing medications, alongside T-cell modulatory therapies aimed at enhancing the body’s immune response to combat cancer and other serious diseases.

This sale by Jonathan Zalevsky, along with the recent trading activity, highlights the ongoing developments within Nektar Therapeutics and its position in the biopharmaceutical industry. The company continues to be a subject of interest among both investors and analysts as it navigates the complexities of drug development and market fluctuations.